{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:13:27Z","timestamp":1787004807407,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1053\/j.gastro.2020.09.041","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T01:38:22Z","timestamp":1601516302000},"page":"88-98.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide Analysis"],"prefix":"10.1053","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-9948","authenticated-orcid":false,"given":"Christopher","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Congly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri L.","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Belletrutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maitreyi","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher N.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2020.09.041_bib1","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2016.02.032","article-title":"Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2020.09.041_bib2","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Mearin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2020.09.041_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5056\/jnm.2011.17.2.131","article-title":"Biopsychosocial model of irritable bowel syndrome","volume":"17","author":"Tanaka","year":"2011","journal-title":"J\u00a0Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2020.09.041_bib4","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1053\/j.gastro.2016.02.027","article-title":"Biopsychosocial aspects of functional gastrointestinal disorders: how central and environmental processes contribute to the development and expression of functional gastrointestinal disorders","volume":"150","author":"Van Oudenhove","year":"2016","journal-title":"Gastroenterology"},{"issue":"4 Suppl 2","key":"10.1053\/j.gastro.2020.09.041_bib5","first-page":"1","article-title":"New and emerging treatment options for irritable bowel syndrome","volume":"11","author":"Lacy","year":"2015","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2020.09.041_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000485407","article-title":"Functional gastrointestinal disorders: complex treatments for complex pathophysiological mechanisms","volume":"35","author":"Mearin","year":"2017","journal-title":"Dig Dis"},{"key":"10.1053\/j.gastro.2020.09.041_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11938-003-0023-8","article-title":"Approach to the patient with severe, refractory irritable bowel syndrome","volume":"6","author":"Olden","year":"2003","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1053\/j.gastro.2020.09.041_bib8","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.bpg.2004.04.012","article-title":"Definition and epidemiology of functional gastrointestinal disorders","volume":"18","author":"Corazziari","year":"2004","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2020.09.041_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S2468-1253(16)30116-9","article-title":"Management of the multiple symptoms of irritable bowel syndrome","volume":"2","author":"Simren","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.09.041_bib10","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1177\/2050640617731968","article-title":"Irritable bowel syndrome diagnosis and management: a simplified algorithm for clinical practice","volume":"5","author":"Moayyedi","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"10.1053\/j.gastro.2020.09.041_bib11","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jama.2015.0954","article-title":"Irritable bowel syndrome: a clinical review","volume":"313","author":"Chey","year":"2015","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2020.09.041_bib12","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.cgh.2016.04.026","article-title":"Effect of yoga in the therapy of irritable bowel syndrome: a systematic review","volume":"14","author":"Schumann","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.09.041_bib13","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1053\/j.gastro.2014.09.001","article-title":"American Gastroenterological Association institute guideline on the pharmacological management of irritable bowel syndrome","volume":"147","author":"Weinberg","year":"2014","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1053\/j.gastro.2020.09.041_bib14","first-page":"101","article-title":"Pharmacotherapy for irritable bowel syndrome","volume":"6","author":"Camilleri","year":"2017","journal-title":"J\u00a0Clin Med"},{"key":"10.1053\/j.gastro.2020.09.041_bib15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1053\/j.gastro.2018.08.063","article-title":"Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018","volume":"156","author":"Peery","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2020.09.041_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ajg.2017.421","article-title":"The prevalence and impact of overlapping Rome IV-diagnosed functional gastrointestinal disorders on somatization, quality of life, and healthcare utilization: a cross-sectional general population study in three countries","volume":"113","author":"Aziz","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2020.09.041_bib17","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis","volume":"10","author":"Lovell","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.09.041_bib18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2036.2003.01456.x","article-title":"The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects","volume":"17","author":"Hungin","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2020.09.041_bib19","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/j.gastro.2012.08.002","article-title":"Burden of gastrointestinal disease in the United States: 2012 update","volume":"143","author":"Peery","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2020.09.041_bib20","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/ajg.2015.128","article-title":"Anxiety and depression increase in a stepwise manner in parallel with multiple FGIDs and symptom severity and frequency","volume":"110","author":"Pinto-Sanchez","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2020.09.041_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/apt.15325","article-title":"Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome","volume":"50","author":"Zamani","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2020.09.041_bib22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/ajg.2013.410","article-title":"The impact of physical complaints, social environment, and psychological functioning on IBS patients\u2019 health perceptions: looking beyond GI symptom severity","volume":"109","author":"Lackner","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2020.09.041_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1053\/j.gastro.2019.04.019","article-title":"Cumulative effects of psychologic distress, visceral hypersensitivity, and abnormal transit on patient-reported outcomes in irritable bowel syndrome","volume":"157","author":"Simren","year":"2019","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1053\/j.gastro.2020.09.041_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13629","article-title":"Reduction in IBS symptom severity is not paralleled by improvement in quality of life in patients with irritable bowel syndrome","volume":"31","author":"Weerts","year":"2019","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2020.09.041_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41395-018-0222-5","article-title":"Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis","volume":"114","author":"Ford","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2020.09.041_bib26","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s41395-018-0396-x","article-title":"Durability and decay of treatment benefit of cognitive behavioral therapy for irritable bowel syndrome: 12-month follow-up","volume":"114","author":"Lackner","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2020.09.041_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.gastro.2018.03.063","article-title":"Improvement in gastrointestinal symptoms after cognitive behavior therapy for refractory irritable bowel syndrome","volume":"155","author":"Lackner","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2020.09.041_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(18)30310-8","article-title":"Efficacy of Individual and Group Hypnotherapy in Irritable Bowel Syndrome (IMAGINE): a multicentre randomised controlled trial","volume":"4","author":"Flik","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1053\/j.gastro.2020.09.041_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023881","article-title":"Cost-effectiveness of internet-delivered cognitive-behavioural therapy for adolescents with irritable bowel syndrome","volume":"9","author":"Sampaio","year":"2019","journal-title":"BMJ Open"},{"key":"10.1053\/j.gastro.2020.09.041_bib30","first-page":"1613","article-title":"Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial","volume":"68","author":"Everitt","year":"2019","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2020.09.041_bib31","first-page":"6","article-title":"Canadian Association of Gastroenterology clinical practice guideline for the management of irritable bowel syndrome (IBS)","volume":"2","author":"Moayyedi","year":"2019","journal-title":"J\u00a0Can Assoc Gastroenterol"},{"key":"10.1053\/j.gastro.2020.09.041_bib32","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/jgh.14830","article-title":"Delivery of care for functional gastrointestinal disorders: a systematic review","volume":"35","author":"Basnayake","year":"2020","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.09.041_bib33","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1155\/2003\/532138","article-title":"Irritable bowel syndrome in primary care: the patients\u2019 and doctors\u2019 views on symptoms, etiology and management","volume":"17","author":"Bijkerk","year":"2003","journal-title":"Can J Gastroenterol"},{"key":"10.1053\/j.gastro.2020.09.041_bib34","first-page":"453","article-title":"Economic burden of irritable bowel syndrome with diarrhea: retrospective analysis of a U.S. commercially insured population","volume":"23","author":"Buono","year":"2017","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1053\/j.gastro.2020.09.041_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12955-017-0611-2","article-title":"Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea","volume":"15","author":"Buono","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"10.1053\/j.gastro.2020.09.041_bib36","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1007\/s10620-010-1196-3","article-title":"Prescribing patterns for the outpatient treatment of constipation in the United States","volume":"55","author":"Trinkley","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2020.09.041_bib37","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.cgh.2011.08.008","article-title":"Increasing frequency of opioid prescriptions for chronic abdominal pain in US outpatient clinics","volume":"9","author":"Dorn","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.09.041_bib39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00019053-200624010-00002","article-title":"Costs of irritable bowel syndrome in the UK and US","volume":"24","author":"Maxion-Bergemann","year":"2006","journal-title":"Pharmacoeconomics"},{"issue":"Suppl A","key":"10.1053\/j.gastro.2020.09.041_bib40","first-page":"89A","article-title":"The economic burden of irritable bowel syndrome in Canada","volume":"13","author":"Bentkover","year":"1999","journal-title":"Can J Gastroenterol"},{"issue":"1","key":"10.1053\/j.gastro.2020.09.041_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13483","article-title":"Subgroups of IBS patients are characterized by specific, reproducible profiles of GI and non-GI symptoms and report differences in healthcare utilization: a population-based study","volume":"31","author":"Polster","year":"2019","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2020.09.041_bib42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cgh.2012.07.019","article-title":"Partner burden in irritable bowel syndrome","volume":"11","author":"Wong","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.09.041_bib43","doi-asserted-by":"crossref","first-page":"895","DOI":"10.14309\/ajg.0000000000000614","article-title":"Chronic constipation in the United States: results from a population-based survey assessing healthcare seeking and use of pharmacotherapy","volume":"115","author":"Oh","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2020.09.041_bib44","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/01.mlr.0000114916.95639.af","article-title":"A\u00a0comparison of the National Ambulatory Medical Care Survey (NAMCS) measurement approach with direct observation of outpatient visits","volume":"42","author":"Gilchrist","year":"2004","journal-title":"Med Care"},{"key":"10.1053\/j.gastro.2020.09.041_bib45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/pds.1118","article-title":"Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation","volume":"15","author":"Sands","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508520352240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508520352240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T15:31:40Z","timestamp":1758036700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508520352240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0016508520352240"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2020.09.041","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide Analysis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2020.09.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the AGA Institute","name":"copyright","label":"Copyright"}]}}